Adalimumab

生物活性

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

IC₅₀ & Target

TNF-α

体外研究
(In Vitro)

Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their

cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study.

MCE has not independently confirmed the accuracy of these methods. They are for

reference only.

体内研究
(In Vivo)

The elimination half-life (t_1/2) of Adalimumab is long (~20 days). The enriched

fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions

documenting good tissue penetration of the drug into the atherosclerotic plaque, without

background fluorescence of the vessel wall after vehicle control injection into

hypercholesterolemic Ldlr^-/- mice.

MCE has not independently confirmed the accuracy of these methods. They are for

reference only.

分子量

145425.42

CAS 号

331731-18-1

中文名称

阿达木单抗；阿达莫单抗

运输条件

Shipping with dry ice.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.